Sesen Bio Inc

Sesen Bio — 2019 Canaccord Genuity Global Growth Conference

53 slides from Sesen Bio's conference presentation, Aug 7, 2019

  1. Slide 1: 2019 Canaccord Genuity Global Growth Conference

    Slide 1: 2019 Canaccord Genuity Global Growth Conference

    2019 Canaccord Genuity Global Growth Conference Thomas Cannell DVM, President and CEO August 7, 2019 NASDAQ SESN

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and Trial and/or that the final data may not be positive with regard to the safety or efficacy of uncertainties. All statements, other than statements of historical facts, contained in thi

  3. Slide 3: Our Path Forward Starts with the Patient Journey

    Slide 3: Our Path Forward Starts with the Patient Journey

    BLOOD IN URINE OUR PATH FORWARD See PCP; therapeutic trial of antibiotics prescribed STARTS WITH THE Still see blood in urine See PATIENT JOURNEY blood in urine; try different antibiotic Confusion and concern on problem Begin tests Referred to Urologist Shock and st CT Scan emotional Preparing for 1

  4. Slide 4: August 2019 Agenda

    Slide 4: August 2019 Agenda

    AUGUST 2019 AGENDA 1. Positive interactions with FDA on May 20th and June 6th results in greater confidence in our regulatory and commercial pathway 2. Updated Phase III data demonstrate a compelling benefit-risk profile with the potential to be BCG and cystectomy-sparing* 3. New market research sup

  5. Slide 5: 2019 Regulatory Update for Vicinium for NMIBC

    Slide 5: 2019 Regulatory Update for Vicinium for NMIBC

    2019 Regulatory Update for Vicinium for NMIBC May 20th Type C CMC Meeting: FDA Accepts Analytical Comparability Plan to Support the BLA and Commercialization of Vicinium for NMIBC • Reached alignment with FDA on primary objective of meeting: acceptance of analytical comparability plan for commercial

  6. Slide 6: Updated Phase III data basis for initiation of BLA submission

    Slide 6: Updated Phase III data basis for initiation of BLA submission

    Updated Phase III data will be the basis for the initiation of the BLA submission anticipated in 4Q 2019 Oncology Products Reviewed by FDA 2006 - 2015 Phase Probability of Approval Products at end of Phase I 5% Products at end of Phase II 8% Products at end of Phase III 33% Products with BLA Submiss

  7. Slide 7: August 2019 Agenda

    Slide 7: August 2019 Agenda

    AUGUST 2019 AGENDA 1. Positive interactions with FDA on May 20th and June 6th results in greater confidence in our regulatory and commercial pathway 2. Updated Phase III data demonstrate a compelling benefit-risk profile with the potential to be BCG and cystectomy-sparing* 3. New market research sup

  8. Slide 8: Vicinium demonstrates a strong benefit-risk profile in Phase III

    Slide 8: Vicinium demonstrates a strong benefit-risk profile in Phase III

    Vicinium demonstrates a strong benefit-risk profile in our Phase III Trial Efficacy Surrogate Time to Health Endpoints Cystectomy Outcomes Benefit : Risk Safety and Tolerability Selectively targets cancer cells while generally avoiding healthy cells Favorable profile relative to BCG, Valstar, checkp

  9. Slide 9: Totality of Phase III data suggest strong benefit-risk profile

    Slide 9: Totality of Phase III data suggest strong benefit-risk profile

    PIII We believe the totality of Phase III data suggest a strong benefit-risk profile All Cohorts Endpoint How Endpoint is Measured Results Complete Response Rate (CRR) • 40% CRR at 3 months Defined as the proportion of patients who show no evidence of high-risk Primary Endpoint • Lower bound of 95%

  10. Slide 10: Duration of Response: longer complete response, higher probability of remaining cancer-free

    Slide 10: Duration of Response: longer complete response, higher probability of remaining cancer-free

    Duration of Response: The longer you have a complete response, the higher the PIII probability of remaining cancer-free CIS Patients Probability of Maintaining Complete Response (CR) for at Each time point a CR is confirmed, the probability of Least One Additional Year* maintaining a CR increases 11

  11. Slide 11: Time to Disease Recurrence in high-risk papillary patients

    Slide 11: Time to Disease Recurrence in high-risk papillary patients

    Time to Disease Recurrence: For high-risk papillary patients who were PIII Papillary treated with Vicinium, 50% are disease-free at 1 year Patients Median time to recurrence is 402 days per Kaplan-Meier estimates (13.2 months) 100 Legend: 80 KM Estimate X Censored Free - 95% CI 60 50% 40 37% % of Pa

  12. Slide 12: Vicinium is cystectomy-sparing by delaying or avoiding cystectomy

    Slide 12: Vicinium is cystectomy-sparing by delaying or avoiding cystectomy

    Our Phase III data suggests Vicinium is cystectomy-sparing by significantly delaying or avoiding cystectomy for patients Your Bladder: A Hero Organ Radical Cystectomy: Life-Altering Surgery � Self-controlled storage organ in � Often a 10 hour or longer surgery the body � In women, removal of the ent

  13. Slide 13: Time to Cystectomy: responders remain cystectomy-free

    Slide 13: Time to Cystectomy: responders remain cystectomy-free

    Time to Cystectomy: Responders have an 88% probability of remaining PIII cystectomy-free 3 years after starting treatment All Cohorts The average responder remains cystectomy-free for 1,035 days vs 631 days for non-responders 100 80 Statistically significant difference for responders vs. non-respond

  14. Slide 14: Key Survival Endpoints

    Slide 14: Key Survival Endpoints

    Key Survival Endpoints: Early survival data are encouraging regarding PIII health outcomes for patients treated with Vicinium All Cohorts Progression-Free Survival Time Point (Evaluable Patients) Progression-Free Survival (95% CI) 6-months (52) 99% (97%-100%) 12-months (25) 96% (90%-100%) 18-months

  15. Slide 15: Safety and Tolerability: Phase II and Phase III consistent

    Slide 15: Safety and Tolerability: Phase II and Phase III consistent

    Safety and Tolerability: Our Phase II and Phase III clinical trials are highly PII & PIII All Cohorts consistent for safety and tolerability Increased dosing and duration of exposure does not appear to lead to an increase in incidence or severity of AEs Phase II Phase III Category Tre a tm e n t-rel

  16. Slide 16: Safety and Tolerability: adverse events by age

    Slide 16: Safety and Tolerability: adverse events by age

    Phase III Phase trial Safety and Tolerability: Mean (range8.1 0 AEs patients:for all Note: 2 Datacohortsfrom all1, of consist& patients (n=133). 3 - 54), Mean treatment Mean AEs/patient 10 0 2 4 6 8 No ageNo The The average patient in the VISTA trial was ~74 years old 9.0 - related AEs for all patie

  17. Slide 17: August 2019 Agenda

    Slide 17: August 2019 Agenda

    AUGUST 2019 AGENDA 1. Positive interactions with FDA on May 20th and June 6th results in greater confidence in our regulatory and commercial pathway 2. Updated Phase III data demonstrate a compelling benefit-risk profile with the potential to be BCG and cystectomy-sparing* 3. New market research sup

  18. Slide 18: Virtuous Cycle: physicians, patients and payers as advocates

    Slide 18: Virtuous Cycle: physicians, patients and payers as advocates

    Virtuous Cycle: High possibility that all three key segments are advocates & take action Physicians (Ancillary HCPs) Patients Payers (Caregivers/ Encourage use of Vicinium before RC (Private/ families) public) Advocate for product reimbursement Sources: Sesen Bio internal market research: Patient Jo

  19. Slide 19: Key drivers of intent to prescribe for high-prescribing Urologists

    Slide 19: Key drivers of intent to prescribe for high-prescribing Urologists

    Safety, MOA and efficacy are all key drivers in intent to prescribe for high- prescribing Urologists Physician Intent to Prescribe Key Drivers of Physician Intent to Prescribe After reviewing the data, high-prescribing Urologists state they would prescribe Vicinium to 10 8.8 9 8.6 8.5 8 Would 7 Pres

  20. Slide 20: High-prescribing Urologists recognize value across safety, MOA and efficacy

    Slide 20: High-prescribing Urologists recognize value across safety, MOA and efficacy

    High-prescribing Urologists recognize the significant value across safety, MOA and efficacy “This is another bladder intravesical treatment available with an even lower risk of side effects than BCG and has a greater ability to prevent recurrence.” Safety & Tolerability “…the fact that it is specifi

  21. Slide 21: Vicinium potential to provide continuity of care for NMIBC

    Slide 21: Vicinium potential to provide continuity of care for NMIBC

    Vicinium has the potential to provide continuity of care for patients with NMIBC Tre a tm e n t w ith Tre a tm e n t w ith >90% of high-prescribing Urologists state Tre a tm e n t P rotocol BCG Vicinium that Vicinium would be very easy to integrate into their practice.* Directed by Urologist 9% Admi

  22. Slide 22: August 2019 Agenda

    Slide 22: August 2019 Agenda

    AUGUST 2019 AGENDA 1. Positive interactions with FDA on May 20th and June 6th results in greater confidence in our regulatory and commercial pathway 2. Updated Phase III data demonstrate a compelling benefit-risk profile with the potential to be BCG and cystectomy-sparing* 3. New market research sup

  23. Slide 23: Microbial manufacturing of Vicinium is simple, reliable and inexpensive

    Slide 23: Microbial manufacturing of Vicinium is simple, reliable and inexpensive

    Microbial manufacturing of Vicinium is simple, reliable and inexpensive 2000 L E. coli Production Bioreactor Centrifugation (bulk solids removal) Clarification (MF for fine solids removal and UF/DF for buffer exchange) Cell Bank Shake flask 5 Column Purification DP Fill Finish (7 mL @ 5mg/mL) 1: Q-S

  24. Slide 24: Sesen Bio Key Highlights

    Slide 24: Sesen Bio Key Highlights

    SESEN BIO KEY HIGHLIGHTS 1. Positive interactions with FDA on May 20th and June 6th results in greater confidence in our regulatory and commercial pathway 2. Updated Phase III data demonstrate a compelling benefit-risk profile with the potential to be BCG and cystectomy-sparing* 3. New market resear

  25. Slide 25: 2019 Outlook

    Slide 25: 2019 Outlook

    2019 Outlook Strengthened Financial Position June 30, 2019 December 31, 2018 Cash and Cash $64.9M $50.4M Equivalents Upcoming Milestones • Three key regulatory events anticipated in 4Q 2019: 1. Type B CMC meeting to align on the submission strategy of the CMC module 2. Type C clinical meeting to dis

  26. Slide 26: Recent and Upcoming IR Events

    Slide 26: Recent and Upcoming IR Events

    Recent and Upcoming IR Events Recent 2019 IR Presentations � Business Update - January 3 � 1Q 2019 Business Update - March 4 � 2Q 2019 Business Update - May 13 � Regulatory Meeting Update - June 10 � Canaccord Genuity Conference - August 7 Anticipated 2019 IR Presentations � Investor Conference - Se

  27. Slide 27: Appendix

    Slide 27: Appendix

    Appendix sesen ca

  28. Slide 28: Vicinium is a single fusion protein that selectively targets cancer cells

    Slide 28: Vicinium is a single fusion protein that selectively targets cancer cells

    Vicinium is a single fusion protein that selectively targets cancer cells Antibody Exotoxin A Linker Fragment Payload • Antibody fragment (scFv) targeting EpCAM linked to a cytotoxic payload (Pseudomonas exotoxin A) to form a single protein • EpCAM over-expressed in cancer cells • Highly selective t

  29. Slide 29: Vicinium: Dual Mechanism of Action

    Slide 29: Vicinium: Dual Mechanism of Action

    Vicinium: Dual Mechanism of Action Mechanism 1: Exotoxin A Payload Kills cell directly Non-cleavable Ligand-checkpoint peptide Linker Vicinium interaction deactivates Antibody Fragment anti-tumor response Checkpoint Vicinium selectively Vicinium does not induce expression T cells recognize targets E

  30. Slide 30: Latest global BCG shortage expected to last through 2019

    Slide 30: Latest global BCG shortage expected to last through 2019

    Latest global BCG shortage expected to last at least through remainder of 2019 2012 2013 2014 2015 2016 2017 2018 2019 Sanofi suspends production Merck announces shortages Sanofi discontinues all global Merck announces supply of BCG Connaught strain of BCG Tice strain production of BCG constraints o

  31. Slide 31: Long-term FDA relationship shaped clinical program in alignment with guidance

    Slide 31: Long-term FDA relationship shaped clinical program in alignment with guidance

    Our long-term relationship with the agency has allowed us to shape our nonclinical and clinical program in alignment with FDA guidance 2018 FDA Guidance Vicinium Clinical Program • Conduct nonclinical studies to assess toxicity in animal models � • Conduct nonclinical studies to demonstrate anti-tum

  32. Slide 32: Phase III Trial: Patient Demographics

    Slide 32: Phase III Trial: Patient Demographics

    Phase III Trial: Patient Demographics COHORT 1 COHORT 2 COHORT 3 CHARACTERISTICS CIS that was refractory or CIS that recurred >6 Papillary tumors (without recurred within 6 months months but ≤11 months of CIS) that were refractory of adequate BCG adequate BCG or recurred within 6 months of adequate

  33. Slide 33: Phase III Evaluable Patient Data Tables by Cohort for CIS

    Slide 33: Phase III Evaluable Patient Data Tables by Cohort for CIS

    PIII Phase III Trial: Evaluable Patient Data Tables by Cohort for Carcinoma in situ CIS patients Cohort 1 (n=82) Complete Response Rate Time Point Evaluable Patients Complete Response Rate (95% Confidence Interval) 3-months n=82 39% (28%-50%) 6-months n=82 26% (17%-36%) 9-months n=82 20% (12%-30%) 1

  34. Slide 34: Additional Vicinium Clinical Data: Phase II vs. Phase III CRR

    Slide 34: Additional Vicinium Clinical Data: Phase II vs. Phase III CRR

    PII & PIII Additional Vicinium Clinical Data CIS Patients Preliminary Phase II vs. Phase III Complete Response Rate Time Point Phase II Pooled CRR (95% Confidence Interval) Phase III Pooled CRR (95% Confidence Interval) 3-months 40% (26%-56%) 40% (30%- 51%) 6-months 27% (15%-42%) 28% (19%-39%) 9-mon

  35. Slide 35: Complete and Partial Response in Phase II

    Slide 35: Complete and Partial Response in Phase II

    Complete and Partial Response: In our Phase II clinical trial, 83% of PII patients had a complete or partial response CIS Patients 3-Month Response ~40% of patients had a complete response Start of Treatment with ~43% of patients had a partial response Vicinium ~17% of patients had no response *Note

  36. Slide 36: Duration of Response: 52% of CIS patients disease-free at 12 months

    Slide 36: Duration of Response: 52% of CIS patients disease-free at 12 months

    Duration of Response: 52% of CIS patients who had a complete response at 3 PIII months remained disease-free for a total of 12 months after starting treatment CIS Patients Median Duration of Response is 287 days (95% CI, 154-NE* days) (9.4 months)** 100 KM Estimate 80 X Censored 95% CI 60 52% 39% 40

  37. Slide 37: Duration of Response: more efficacious in CIS patients with less BCG

    Slide 37: Duration of Response: more efficacious in CIS patients with less BCG

    Duration of Response: Vicinium is generally more efficacious in CIS patients PIII treated with less BCG CIS Patients The BCG shortage may cause a new normal wherein patients receive less BCG 100 Legend: 7-9 BCG instillations ≥10 BCG instillations 80 X Censored 60 Median 40 20 % of Patients % of Pati

  38. Slide 38: Complete Response Rate: 95% CI rules out clinically unmeaningful CRR

    Slide 38: Complete Response Rate: 95% CI rules out clinically unmeaningful CRR

    PIII Complete Response Rate: We believe our 95% confidence interval rules out CIS Patients the CRR for Valstar and a clinically unmeaningful CRR Complete Response Rate 40% Legend: 39% 35% 95% CI 30% 28% Vicinium 25% 26% Duration of Response for patients with CR at 6 months: 1 20% 19% Valstar: 13.5 m

  39. Slide 39: Time to Cystectomy: average of 930 days

    Slide 39: Time to Cystectomy: average of 930 days

    Time to Cystectomy: Patients treated with Vicinium remain cystectomy- PIII free for an average of 930 days (~31 months) after treatment with Vicinium All Cohorts >75% of patients remain cystectomy-free for at least 2.5 years 100 80 Free - 60 Median 40 Legend: KM Estimate 20 X Censored % of Patients

  40. Slide 40: Safety and Tolerability: AEs generally low grade

    Slide 40: Safety and Tolerability: AEs generally low grade

    Safety and Tolerability: In our Phase III trial, AEs were generally low grade PIII and resulted in a low rate of discontinuation All Cohorts Tre a tm e n t-Related AEs All AEs (% patients) (% patients) Any AE Urinary tract infection Dysuria Hematuria Pollakiuria (frequency of urination) Micturition

  41. Slide 41: Bladder cancer is highly prevalent with tremendous unmet medical need

    Slide 41: Bladder cancer is highly prevalent with tremendous unmet medical need

    Bladder cancer is highly prevalent with tremendous unmet medical need ~550,000 New Cases Each Year Globally1 • $4B+ in annual treatment costs for bladder cancer in the US alone2 Europe 3 ~195K • 75-85% diagnosed as NMIBC North America ~95K • Limited treatment options for high-risk NMIBC - Only three

  42. Slide 42: Carcinoma in situ: the most difficult form of NMIBC to treat

    Slide 42: Carcinoma in situ: the most difficult form of NMIBC to treat

    Carcinoma in situ: the most difficult form of NMIBC to treat Carcinoma in situ vs. Normal Bladder Lining: Clinical Trial Implications: • Field change disease often involving the entire bladder lining that is very difficult to treat • Failed on two or more courses of BCG, which is the gold standard f

  43. Slide 43: Radical cystectomy remains recommended option after BCG failure

    Slide 43: Radical cystectomy remains recommended option after BCG failure

    Radical cystectomy remains recommended treatment option after BCG failure 60-70% lifetime risk of cystectomy associated with NMIBC1 • Long, complex surgical procedure (10+ hours) • Significant rates of morbidity (30-60% within 90 days) and mortality (2-9% within 6 months)2 – 64% complication rate wi

  44. Slide 44: Significant unmet need for innovative therapies to treat NMIBC

    Slide 44: Significant unmet need for innovative therapies to treat NMIBC

    Significant unmet need for innovative medical therapies to treat NMIBC Only 3 products have ever been approved by the FDA for NMIBC Product FDA Approval Additional Product Information Thiotepa 1959 Rarely used in current treatment regimens BCG* 1989 (Tice) Recommended first line treatment Valstar 19

  45. Slide 45: Bladder cancer patient experience is among the poorest

    Slide 45: Bladder cancer patient experience is among the poorest

    Patient surveys have shown that the experience of those with bladder cancer is one of the poorest1 Key Drivers of Poor Patient Journey in Bladder Cancer vs. Average Experience Among 5 Most Common Cancers2 90 86 80 75 72 68 70 65 60 50 47 40 30 % of Patients Who HadWho Experience % of Patients 20 10

  46. Slide 46: Addressable Market (US)

    Slide 46: Addressable Market (US)

    Addressable Market (US) Annual Volume ~80K1 Patients diagnosed with bladder cancer ~75% - 85% of bladder cancer diagnoses are NMIBC2 Patients diagnosed with NMIBC ~40% - 50% of NMIBCs are high-risk3 Patients with high-risk NMIBC: Papillary: ~80%2 CIS: ~20%2 ~50% - 90% of BCG treatments fail or disea

  47. Slide 47: Pricing and Reimbursement (US)

    Slide 47: Pricing and Reimbursement (US)

    Pricing and Reimbursement (US) Price Reference Payer Management Responses (Annual Cost)1 to Pricing2 100% $200K CI 3 Price Range of Checkpoint CI 2 Inhibitors (CIs) for CI 1 Urothelial Carcinoma $150K 50% Proportion Payers of Proportion $100K 0% $30 K $60 K $90 K $150 K $50K Unrestricted Coverage PA

  48. Slide 48: OUS opportunity for Vicinium is 2-3 times larger than US

    Slide 48: OUS opportunity for Vicinium is 2-3 times larger than US

    We estimate the OUS opportunity for Vicinium is 2-3 times larger than the US Geography Est. Incidence Relative to U.S.1 Est. Price Relative to U.S.2 EU5 1.2 – 1.4 0.50 – 0.71 Japan 0.4 – 0.6 0.60 – 0.70 Rest of Europe 1.0 – 1.2 0.60 – 1.10 (Not including EU5) North America 0.1 – 0.3 0.55 – 0.70 (Not

  49. Slide 49: Only ~1,500 Urologists account for bulk of NMIBC treatment

    Slide 49: Only ~1,500 Urologists account for bulk of NMIBC treatment

    Only ~1,500 Urologists account for the bulk of NMIBC treatment and are concentrated in group practices allowing for a very efficient commercial model ~60% of Urology practices have ≥5 Urologists1 BCG Prescribers2 100% 90% 80% 70% 60% ~1,500 Urologists treat 75% of patients 50% % of Patients of % 40%

  50. Slide 50: Comparability Strategy for Vicinium accepted by the FDA

    Slide 50: Comparability Strategy for Vicinium accepted by the FDA

    The Comparability Strategy for Vicinium has been accepted by the FDA* Guidance “If a manufacturer can provide assurance of comparability through analytical studies alone, nonclinical or clinical studies with the post-change product are not warranted.”1 Sesen’s analytical comparability plan is compri

  51. Slide 51: Experienced partners for global manufacturing and supply of Vicinium

    Slide 51: Experienced partners for global manufacturing and supply of Vicinium

    We have experienced partners for the global manufacturing and supply of Vicinium � Licensed for commercial production of 8 approved products � 25+ years developing and manufacturing biologics � 310+ protein-based therapeutics in development and/or manufacturing � Proven track record with FDA and wor

  52. Slide 52: Vicinium: A single cGMP Manufacturing Process

    Slide 52: Vicinium: A single cGMP Manufacturing Process

    Vicinium: A single cGMP Manufacturing Process Vicinium cGMP manufacturing process producing a single fusion protein � Inexpensive � Reliable � Simple (linear) QA QA Purification Release Fill/Finish Release Bioreactor (Generates Drug (Generates Drug Market Substance) Product) Single cGMP process ADCs

  53. Slide 53: Vicinium Patent Life

    Slide 53: Vicinium Patent Life

    Vicinium Patent Life Pending Applications Dosing Strategies for Targeting EpCAM positive bladder cancer. If allowed, Stabilized Chimeric Immunoglobulins would expire in 2036 or later. (April 2020 - July 2020) US: 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 20

Source: SEC EDGAR · 8-K filed Aug 7, 2019

More decks from Sesen Bio Inc